How do you interpret NIAGARA efficacy given that adjuvant nivolumab was not administered in the comparator arm?  

NIAGARA was designed and conducted prior to the approval/availability of adjuvant Nivolumab. We cannot compare the perioperative regimen of NIAGARA to adjuvant Nivolumab since the efficacy of the addition of Durvalumab to cisplatin/gemcitabine is reflected in the downstaging at the time of surgery c...

The NIAGARA trial evaluated the role of durvalumab as neoadjuvant/adjuvant treatment in muscle-invasive bladder cancer (MIBC). The combination chemoimmunotherapy (cisplatin, gemcitabine, and durvalumab) was given for 3 months prior to radical cystectomy, followed by adjuvant durvalumab every 4 weeks...